首页 产业/市场分类 出版商一览 Email 通知 GII媒体代理会议 公司简介 联络我们
- English Japanese Korean
首页 > 市场调查报告书 > 制药 > 癌症 > 乳癌、大肠癌、细胞死亡分析
产业/市场分类
制药 (4823)
肥胖症治疗 (44)
非专利药 (129)
疫苗 (181)
神经疾病 (172)
骨头疾病治疗 (37)
动物用医药 (18)
处方药 (156)
规章 (130)
感染疾病 (347)
精神病 (85)
制药企业 (526)
糖尿病 (191)
癌症 (903)
药物开发 (1458)
DDS (182)
OTC 非处方药 (150)
市场调查报告书

乳癌、大肠癌、细胞死亡分析

Triple Analysis: Breast Cancer, Colorectal Cancer and Apoptosis

出版商 BioSeeker Group AB
出版日期 2011年12月 商品编码 177187
内容信息 英文 3586 Pages
价格
US $ 5175 PDF by E-mail


乳癌、大肠癌、细胞死亡分析 是由出版商BioSeeker Group AB在2011年12月所出版的。 这份英文市场调查报告书包含3586 Pages 价格从美金5175起跳。

简介

本报告针对乳癌、大肠癌、相关药物开发策略、细胞死亡机制、目的、效果进行调查分析,提供各药剂目的策略、复合策略竞争基准、临床实验与分析计划,目录介绍如下。

第1章 乳癌

  • 本报告范围
  • 以最佳治疗结果与投资回收率为前提的乳癌治疗目标
  • 新药登场:乳癌治疗药物管道的特定药剂目标策略,是否有成熟的药物目标策略、独特性、有临床评价
  • 使用中的复合策略:复合策略分类竞争基准
  • 临床实验与分析计划
  • 药物索引
  • 企业索引
  • 图表

第2章 大肠癌

  • 本报告范围
  • 以最佳治疗结果与投资回收率为前提的大肠癌治疗目标
  • 新药登场:开发阶段分类大肠癌药物目标策略
  • 使用中的复合策略:复合策略分类竞争基准
  • 临床实验与分析计划
  • 免责事项
  • 药物索引
  • 企业索引
  • 图表

第3章 细胞死亡

  • 本报告范围
  • 以最佳治疗结果与投资回收率为前提的治疗目标
  • 新药登场:癌症细胞死亡治疗药物管道的特定药剂目标策略,是否有成熟的药物目标策略、独特性、有临床评价
  • 使用中的复合策略:复合策略分类竞争基准
  • 药物影响与胜肽的癌适应症
  • 临床实验与分析计划
  • 药物索引
  • 企业索引
  • 图表

目录

Abstract

This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Colorectal Cancer and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Table of Contents

Key Topics Covered:

Part I: Breast Cancer

  • 5.1. The Scope of this Report 29
  • 6. Consider the Therapeutic Breast Cancer Target for the Highest Therapeutic Outcome and Return on Investment (207 Drug Targets) 33-376
  • 7. The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Strategies Identified in the Breast Cancer Therapeutic Pipeline? (193 Drug Target Strategies and 405 Drugs) 377-441
  • 8. Compound Strategies at Work: Competitive Benchmarking of Breast Cancer Drugs by Compound Strategy (8 Different Compound Strategies) 442-488
  • 9. Pipeline and Portfolio Planning: Competitive Benchmarking of Breast Cancer Therapeutic Pipeline by Investigator (220 Investigators) 489-891
  • 11. Drug Index 893
  • 12. Company Index 905
  • Figures: Includes 7 Figures
  • Tables: Includes 274 Tables
  • Total Number of Pages: 913

Part II: Colorectal Cancer

  • 5.1. The Scope of this Report 28
  • 6. Consider the Therapeutic Target Among Colorectal Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (210 Drug Targets) 32-451
  • 7. Emerging New Products to Established Ones: Drug Target Strategies of Colorectal Cancer Drugs by their Highest Stage of Development (205 Drug Target Strategies and 347 Colorectal Cancer Drugs) 452-699
  • 8. Compound Strategies at Work: Competitive Benchmarking of Colorectal Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-745
  • 9. Pipeline and Portfolio Planning: Competitive Benchmarking of the Colorectal Cancer Drug Pipeline by Investigator (182 Companies) 746-1,039
  • 10. Disclaimer 1040
  • 11. Drug Index 1041
  • 12. Company Index 1050
  • Figures: Includes 6 Figures
  • Tables: Includes 242 Tables
  • Total Number of Pages: 1,056

Part III: Apoptosis

  • 5.1 The Scope of this Report 27
  • 6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (146 Drug Targets) 32-276
  • 7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Cancer Apoptotic Therapeutic Pipeline? (120 Drug Target Strategies and 171 Drugs) 277-311
  • 8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Drugs in Oncology by Compound Type (7 Different Compound Strategies) 312-355
  • 9 Selecting Cancer Indications for Apoptotic Therapeutics (53 Cancer Indications) 356-440
  • 10 Portfolio Planning: Competitive Benchmarking of Apoptotic Cancer Therapeutic Pipeline by Investigator (125 Investigators) 441-793
  • 12 Drug Index 794
  • 13 Company Index 799
  • Figures: Includes 6 Figures
  • Tables: Includes 248 Tables
  • Total Number of Pages: 803

Featured Companies:

This Report Includes the Following Companies:

  • A&G Pharmaceutical
  • Abbott
  • Abiogen
  • Abraxis BioScience
  • Access
  • Adherex
  • Advanced Life Sciences
  • Advaxis
  • AEgera
  • Aeterna Zentaris
  • Affibody
  • Affimed Therapeutics
  • Aida Pharmaceuticals
  • Alchemia
  • Alethia Biotherapeutics
  • Allos Therapeutics
  • Alnis Biosciences
  • Alnylam
  • AlphaVax
  • Alseres Pharmaceuticals
  • Ambrilia Biopharma
  • Amgen
  • Anavex Life Sciences
  • AngioChem
  • Antisense Pharma
  • Antisoma
  • Aphios
  • ApopLogic Pharmaceuticals
  • Apotex
  • Apthera
  • Archer Biosciences
  • Ariad
  • Arno Therapeutics
  • ArQule
  • Array BioPharma
  • Ascend Therapeutics
  • Astellas
  • AstraZeneca
  • Attenuon
  • AVEO
  • AVI BioPharma
  • Bavarian Nordic
  • Bayer
  • Betagenon
  • Betapharma
  • BioAlliance Pharma
  • BioAxone
  • Biocompatibles
  • Biogen Idec
  • BioInvent
  • Bionovo
  • BioNumerik
  • BioVex
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • BTG
  • Callisto Pharmaceuticals
  • Can-Fite BioPharma
  • Cancer Advances
  • Cancer Research Technology
  • Cel-Sci
  • Celator Pharmaceuticals
  • Celera
  • Celgene
  • Cell Genesys
  • Cell Therapeutics
  • Celldex Therapeutics
  • Cellmid
  • Celsion
  • Celtic Pharma
  • Center of Molecular Immunology
  • Cephalon
  • CG Therapeutics
  • ChemGenex Pharmaceuticals
  • ChemoCentryx
  • Chemokine Therapeutics
  • Chiesi
  • Choongwae
  • Circadian Technologies
  • Clavis Pharma
  • CompleGen
  • Cosmo Pharmaceuticals
  • CuraGen
  • CureTech
  • Curis
  • Cyclacel
  • Cylene Pharmaceuticals
  • Cynvec
  • CytImmune Sciences
  • Cytochroma
  • Cytokinetics
  • CytRx
  • Daewoong
  • Daiichi Sankyo
  • Dainippon Sumitomo Pharma
  • Debiopharm
  • Deciphera Pharmaceuticals
  • Dendreon
  • Dong-A
  • Dongkook Pharm
  • Douglas
  • Dynavax Technologies
  • ECI
  • EGEN Inc
  • Eisai
  • Elan
  • Elara Pharmaceuticals
  • Eli Lilly
  • Endoceutics
  • Enkam Pharmaceuticals
  • EntreMed
  • Enzon
  • Epeius Biotechnologies
  • EpiCept
  • Etubics
  • Eucodis
  • Exelixis
  • FasTrack Pharmaceuticals
  • Fresenius
  • Genentech
  • Generex
  • Genmab
  • Genta
  • GenVec
  • Genzyme
  • Geron
  • Gilead Sciences
  • GlaxoSmithKline
  • Gloucester Pharmaceuticals
  • GlycoGenesys
  • GlyTag
  • Got-a-Gene
  • Gradalis
  • Green Cross
  • Heidelberg Pharma
  • Hoffmann-La Roche
  • Hospira
  • Human Genome Sciences
  • Idera Pharmaceuticals
  • IkerChem
  • Immunocore
  • ImmunoGen
  • Immunomedics
  • Immunotope
  • Immutep
  • Incyte Corporation
  • Inex
  • Infinity Pharmaceuticals
  • Innate Pharma
  • InNexus Biotechnology
  • Inovio
  • Insmed
  • Insys Therapeutics
  • Intarcia Therapeutics
  • Intezyne Technologies
  • Intradigm
  • Introgen Therapeutics
  • Ipsen
  • ISA Pharmaceuticals
  • Isis Pharmaceuticals
  • ISU ABXIS
  • Ivy Medical Chemicals
  • Jennerex Biotherapeutics
  • Johnson & Johnson
  • Kalypsys
  • Kiadis
  • Kyowa Hakko Kirin
  • Labopharm
  • LEAD Therapeutics
  • Leo
  • Ligand
  • Lorus Therapeutics
  • MacroGenics
  • Marillion Pharmaceuticals
  • MDRNA
  • Meda
  • Medarex
  • MediGene
  • MedImmune
  • Mediolanum
  • Medisyn Technologies
  • Meiji
  • Menarini
  • Merck & Co
  • Merck KGaA
  • Merrimack
  • Mersana Therapeutics
  • MethylGene
  • Micromet
  • Mitsubishi Tanabe Pharma
  • MolMed
  • Mologen
  • NanoMed Pharmaceuticals
  • Nektar Therapeutics
  • Nemod Biotherapeutics
  • NeoPharm
  • Nerviano Medical Sciences
  • NexGenix Pharmaceuticals
  • NicOx
  • Nidus Laboratories
  • NIH
  • Nippon Kayaku
  • Non-industrial source
  • Novartis
  • Novelix
  • Novogen
  • Nycomed Pharma
  • OncoGenex Pharmaceuticals
  • OncoMed
  • OncoMune
  • Onconova
  • Oncothyreon
  • Oncozyme Pharma
  • Onyvax
  • Orca Therapeutics
  • Orchestra Therapeutics
  • Orion Pharma
  • OSI Pharmaceuticals
  • Oxford BioMedica
  • OXiGENE
  • Paladin Labs
  • PanaGin
  • Pantarhei Bioscience
  • PepTcell
  • Peregrine Pharmaceuticals
  • Pfizer
  • Pharmaclon
  • Pharmacyclics
  • PharmaGap
  • PharmaMar
  • Pharmexa
  • Pharminox
  • PheneX
  • Philogen
  • Pierre Fabre
  • Plexxikon
  • POZEN
  • Pro-Pharmaceuticals
  • ProStrakan
  • Protherics
  • Protox Therapeutics
  • PTC Therapeutics
  • R&R
  • Radient Pharmaceuticals
  • Raptor Pharmaceutical
  • Reata Pharmaceuticals
  • Receptor BioLogix
  • Regeneron
  • Regulon
  • Repros Therapeutics
  • RESprotect
  • Rigel
  • Samyang
  • Sanofi-Aventis
  • Santaris Pharma
  • Sareum
  • Savient Pharmaceuticals
  • Schering-Plough
  • Selvita
  • Semafore Pharmaceuticals
  • Shire
  • Sigma-Tau
  • Simcere Pharmaceuticals
  • Spirogen
  • SRI International
  • SuperGen
  • Supratek Pharma
  • Switch Pharma
  • SynDevRx
  • Synta Pharmaceuticals
  • Taiho
  • Takeda
  • Talon Therapeutics
  • Targa Therapeutics
  • Targepeutics
  • Tau Therapeutics
  • Taxolog
  • Telik
  • Teva
  • Thallion Pharmaceuticals
  • The Genetics Company
  • Therion Biologics
  • ThromboGenics
  • Tigris Pharmaceuticals
  • Titan Pharmaceuticals
  • to-BBB
  • TopoTarget
  • Tracon Pharmaceuticals
  • Tragara Pharmaceuticals
  • Transgene
  • Trion Pharma
  • Vaccinex
  • Vascular Biogenics
  • Vernalis
  • Vertex Pharmaceuticals
  • Vical
  • Wilex
  • Vion Pharmaceuticals
  • VioQuest
  • VioQuest Pharmaceuticals
  • Viragen
  • Viralytics
  • ViroMed
  • ViroTarg
  • Wyeth
  • Xerion
  • Xoma
  • Yakult Honsha
  • YM BioSciences
  • Zensun
  • Zhejiang Beta Pharma
  • Zydus Cadila
  • ZymoGenetics

Featured Drugs:

A Shortlist of Drugs Included are:

  • 2-methoxyestradiol
  • ABT-263
  • AEG-35156
  • aflibercept
  • afutuzumab
  • alvocidib
  • anastrozole
  • Angiozyme
  • Apomab
  • ARQ-197
  • AS-1411
  • atiprimod dimaleate
  • ATN-224
  • belinostat
  • bevacizumab
  • brivanib alaninate
  • BSI-201
  • BZL-101
  • canfosfamide hydrochloride
  • capecitabine
  • catumaxomab
  • CBLC-102
  • cediranib
  • cenersen
  • cetuximab
  • cintredekin besudotox
  • combretastatin A-4 prodrug
  • conatumumab
  • CS-1008
  • denosumab
  • docetaxel
  • doxifluridine
  • doxorubicin
  • dulanermin
  • epirubicin
  • everolimus
  • exemestane
  • fadrozole
  • formestane
  • fulvestrant
  • GCS-100LE
  • goserelin
  • GRN-163L
  • HE-3235
  • idronoxil
  • indisulam
  • INGN-241
  • INGN-401
  • interferon
  • interferon gamma
  • irinotecan bead
  • irinotecan hydrochloride
  • ISIS-23722
  • kahalalide F
  • lapatinib ditosylate
  • lasofoxifene
  • letrozole
  • leuprorelin
  • lonaprisan
  • lumiliximab
  • mapatumumab
  • MGCD-0103
  • MGN-1703
  • mitoxantrone
  • MKC-1
  • motexafin gadolinium
  • neratinib
  • Nudoxa
  • oblimersen sodium
  • paclitaxel
  • panitumumab
  • panobinostat
  • PARP inhibitors
  • PAT-SC1
  • patupilone
  • pazopanib hydrochloride
  • PCI-24781
  • perifosine
  • pertuzumab
  • pirarubicin
  • plitidepsin
  • quarfloxacin
  • raloxifene hydrochloride
  • raltitrexed
  • ramucirumab
  • regorafenib
  • retaspimycin
  • Rh-Apo2L
  • sagopilone
  • seliciclib
  • Stimuvax
  • sunitinib malate
  • tamoxifen
  • tegafur + uracil
  • tegafur + uracil + leucovorin
  • tigapotide triflutate
  • TLN-232
  • toremifene citrate
  • trastuzumab
  • triciribine
  • trilostane
  • triptorelin pamoate
  • TRU-016
  • TS-1
  • voreloxin
  • VX-944
  • XL-647
Back to Top